Prescription Pattern Analysis of Antidiabetic Drugs in Diabetes Mellitus and Associated Comorbidities

Mohd. Mahmood, R. C. Reddy, J. Lahari, S. Fatima, P. Shinde, S. An, Reddy, P. PranaliS.
{"title":"Prescription Pattern Analysis of Antidiabetic Drugs in Diabetes Mellitus and Associated Comorbidities","authors":"Mohd. Mahmood, R. C. Reddy, J. Lahari, S. Fatima, P. Shinde, S. An, Reddy, P. PranaliS.","doi":"10.4172/CLINICAL-INVESTIGATION.1000123","DOIUrl":null,"url":null,"abstract":"Background: The treatment options for Diabetes mellitus and their prescribing has increased over years. This needs appropriate selection of drugs. The main objective of this study was to highlight the current prescribing trends in Diabetes mellitus patients with other co-morbid conditions. Methods: A prospective observational study was conducted on inpatients admitted to various wards in a tertiary care hospital for period of 6 months between October 2016- March 2017. Prescriptions of the patients are collected in a designed questionnaire form and the relevant information is recorded and analysed. Results: 235 patient prescription patterns were studied, out of which 62.97% were males and 37.02% were females. Most of the patients were in the age group of 41-60. Hypertension was the most commonly found co-morbid condition. Rapid acting insulin was mostly prescribed during hospital stay. Metformin was the commonly prescribed oral hypoglycemic agent followed by glimeperide. Conclusion: The adverse drug reactions can be minimized by replacing the drugs with novel therapeutic agents like Glucagon-like peptide agonist, Dipeptidyl peptidase inhibitors and Sodium-glucose transport inhibitors. The management of drug interactions should be done by clinical significance and correlation","PeriodicalId":10369,"journal":{"name":"Clinical investigation","volume":"21 2 1","pages":"4-12"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"13","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/CLINICAL-INVESTIGATION.1000123","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 13

Abstract

Background: The treatment options for Diabetes mellitus and their prescribing has increased over years. This needs appropriate selection of drugs. The main objective of this study was to highlight the current prescribing trends in Diabetes mellitus patients with other co-morbid conditions. Methods: A prospective observational study was conducted on inpatients admitted to various wards in a tertiary care hospital for period of 6 months between October 2016- March 2017. Prescriptions of the patients are collected in a designed questionnaire form and the relevant information is recorded and analysed. Results: 235 patient prescription patterns were studied, out of which 62.97% were males and 37.02% were females. Most of the patients were in the age group of 41-60. Hypertension was the most commonly found co-morbid condition. Rapid acting insulin was mostly prescribed during hospital stay. Metformin was the commonly prescribed oral hypoglycemic agent followed by glimeperide. Conclusion: The adverse drug reactions can be minimized by replacing the drugs with novel therapeutic agents like Glucagon-like peptide agonist, Dipeptidyl peptidase inhibitors and Sodium-glucose transport inhibitors. The management of drug interactions should be done by clinical significance and correlation
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
糖尿病及相关合并症患者降糖药处方模式分析
背景:糖尿病的治疗方案及其处方逐年增加。这需要适当选择药物。本研究的主要目的是强调当前糖尿病患者合并其他合并症的处方趋势。方法:对某三级医院2016年10月- 2017年3月6个月的各病房住院患者进行前瞻性观察研究。以设计的问卷形式收集患者的处方,记录相关信息并进行分析。结果:共研究了235例患者的处方模式,其中男性占62.97%,女性占37.02%。大多数患者年龄在41-60岁之间。高血压是最常见的合并症。速效胰岛素主要是在住院期间开的。二甲双胍是常用的口服降糖药,其次是格列美脲。结论:采用胰高血糖素样肽激动剂、二肽基肽酶抑制剂、钠-葡萄糖转运抑制剂等新型治疗药物替代药物,可减少不良反应。药物相互作用的管理应根据临床意义和相关性进行
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Targeting TGF-beta pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19 A Prospective on Allergic Rhinitis Use of Cladribine for multiple sclerosis treatment: An image article Thalidomide may be an effective medicine for Blau Syndrome Prophylactic administration of a clinically safe low dose of the COVID-19 drug candidate Rejuveinix (RJX) effectively prevents fatal cytokine storm and mitigates inflammatory organ injury in a mouse model of sepsis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1